Treating advanced melanoma: current insights and opportunities. - sprookjes - yvandenbroek - TriplyDB

Treating advanced melanoma: current insights and opportunities.

Treating advanced melanoma: current insights and opportunities.

http://www.wikidata.org/entity/Q38250316

about

Somatic DNA mutation analysis in targeted therapy of solid tumours Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin.Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis of Cutaneous Melanoma.SHP2 phosphatase as a novel therapeutic target for melanoma treatment.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.A practical guide to the handling and administration of talimogene laherparepvec in Europe.Australian Multicenter Study of Isolated Limb Infusion for Melanoma.Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis

P2860

Q26770324-9FF3D298-DAE3-4B59-BF5D-34826A46A5AD Q28084243-F18CDBEC-61A3-455D-9F55-E849F88F8793 Q36288343-C029536D-FBB5-43CA-ABCB-F7CB4A2BDD1D Q36544964-293971C9-502D-47E8-8975-C21A4E5E4562 Q37295253-6E6CE0D9-A60F-4A71-9041-B78ADD46C541 Q37669014-E35ED3AF-6123-4592-A079-98A232CCD54B Q37687479-FF6A5200-E8F4-4DCC-8EFE-811027D5A1C0 Q38584379-6E3C0FB5-6334-4041-945C-86B2B348CFB7 Q38630561-49AA0293-487B-4C21-B185-9940CE695518 Q38849515-73A2C828-0BC7-40C9-BAC7-D5DD4B23D02A Q40080717-2935DCD2-2EF0-48EA-8DC6-A1F3886533B0 Q40307423-4F192B2A-59C4-4C9C-A5F7-18EDA407CCC3 Q41826057-38ABB7D7-79AC-4945-8396-ABCA2B750DFC Q58613151-912DE152-CE5E-4F34-AD1F-B425DCE246B2

P2860

Treating advanced melanoma: current insights and opportunities.

http://www.wikidata.org/entity/Q38250316

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Treating advanced melanoma: current insights and opportunities.

@en

type

label

Treating advanced melanoma: current insights and opportunities.

@en

prefLabel

Treating advanced melanoma: current insights and opportunities.

@en

P1433

Q38250316-9FA577BF-5DA5-4D96-989D-9818C4FC482E

P1476

Q38250316-D8A84AAC-A6C1-487C-8856-763C1CDF153F

P2093

Q38250316-D896FDF2-776F-4D43-A01C-0D39F08F8C1D

P2860

Q38250316-034B18A3-2567-4C96-96A6-E26A35CB7B2E

Q38250316-064C4748-DF05-4777-B142-1D400194BCE5

Q38250316-068DE811-8092-4DCA-BA8A-05487D228271

Q38250316-0A4E5377-0459-4CD9-93DA-78A4085F61F3

Q38250316-0E9A1141-EA38-4EFF-A98B-62E3830F0534

Q38250316-1186C480-D18E-40D7-8FD4-B71FB5317618

Q38250316-1AE1B068-0031-423D-AE3C-F6D77502FD60

Q38250316-1AE4E39B-B9B5-4D71-86BF-100C441E6510

Q38250316-21E89146-29B7-444B-8C1F-71CA24704C9E

Q38250316-23612424-ED28-4FBF-BB21-7C73D17B6167

P304

Q38250316-31D688D8-917F-4FE6-9435-9CAB0912AE34

P31

Q38250316-087cd1b9-9084-4ca9-8def-401672284b70

Q38250316-1BE24BA9-C81D-41F6-B8C1-1FAF476ACD9D

P356

Q38250316-F387C1C8-527C-47D8-86B0-96A3D9FD4F4F

P407

Q38250316-C450E65A-B687-4812-925C-355BE7F1D2F6

P478

Q38250316-84804767-8574-4C71-ACCC-AD5015F57F6D

P50

Q38250316-B94E153E-121B-473D-BB3D-A9C512F8BD3E

P577

Q38250316-F3C38D4E-9FBE-46B0-B935-4D4B4B894120

P698

Q38250316-745AC2AE-7C5A-414D-949B-207F5DB70904

P932

Q38250316-CC61E890-FE92-4CD5-9C0B-E43EF203EC78

P356

P1433

Cancer Management and Research

P1476

Treating advanced melanoma: current insights and opportunities

@en

P2093

Michael Tronnier

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Pathways and therapeutic targets in melanoma

Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape.

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Sunitinib therapy for melanoma patients with KIT mutations.

P304

349-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S49494

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Josh Mitteldorf

P577

2014-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25228821

http://www.w3.org/2001/XMLSchema#string

P932

4164110

http://www.w3.org/2001/XMLSchema#string